• Professional headshot of Tamar Thompson
    Image attribution tooltip
    Permission granted by Alexion

    United by inequity: The healthcare disparities plaguing rare disease patients and Black Americans

    Guided by her personal experiences, Tamar Thompson is aiming to improve rare disease care through her advocacy work at Alexion, AstraZeneca Rare Disease.

    By Alexandra Pecci • Feb. 7, 2023
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images

    Roche, Chiesi and the FDA change major leadership roles as they strive for growth in 2023

    From Roche’s new pharma chief to the departure of the FDA’s gene therapy head, these moves are bound to shake up the industry.

    By Feb. 6, 2023
  • The Federal Trade Commission headquarters is pictured in Washington, D.C. The agency's proposed noncompete ban may face legal challenges on several grounds.
    Image attribution tooltip
    RiverNorthPhotography via Getty Images

    Antitrust watchdogs have pharma in their sights, and the landscape is getting thornier

    The FTC and DOJ are heightening antitrust enforcement, and pharma deals are a prime target.

    By Feb. 2, 2023
  • Pfizer CEO Albert Burl and company executives
    Image attribution tooltip
    Drew Angerer via Getty Images

    Execs at Pfizer, Novartis, Amgen and GSK tackle shifting priorities — reflecting the state of Big Pharma

    A menagerie of earnings calls this week showed where the Big Pharma players stand in 2023.

    By Feb. 2, 2023
  • Yesmean Wahdan Bayer
    Image attribution tooltip
    Permission granted by Yesmean Wahdan Bayer

    Woman of the Week: Bayer’s Dr. Yesmean Wahdan

    The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

    By Feb. 1, 2023
  • Marc de Garidel, CEO, CinCor
    Image attribution tooltip
    Permission granted by CinCor

    This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

    With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.

    By Jan. 31, 2023
  • scale
    Image attribution tooltip
    Stock via Getty Images

    Weight loss drugs: the promise and pitfalls

    GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.

    By Kelly Bilodeau • Jan. 30, 2023
  • Sponsored by GoodRx

    Lessons from GoodRx’s “Guide to Successful Copay Programs”

    Download the complimentary Guide to Successful Copay Programs that delivers actionable insights to pharma leaders.

    Jan. 30, 2023
  • A brown building with white vertical sign with the Twitter logo
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images

    With Twitter in flux, pharma is turning to alternative social spaces

    Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging.

    By Jan. 26, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    By Jan. 26, 2023
  • Lauren Lazar Calcium
    Image attribution tooltip
    Permission granted by Lauren Lazar Calcium

    Woman of the Week: Dr. Lauren Lazar

    As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

    By Jan. 25, 2023
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola via Getty Images

    Economic crisis? J&J execs say that won’t stop them from hitting $60B target

    The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times.

    By Jan. 25, 2023
  • High angle shot of a group of medical practitioners analyzing x-rays on a digital tablet in a hospital.
    Image attribution tooltip
    Stock via Getty Images

    Report reveals murky picture of clinical trial diversity gains

    Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

    By Alexandra Pecci • Jan. 24, 2023
  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    magicmine, iStock / Getty Images Plus via Getty Images

    AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships

    A longtime leader in the respiratory space, AstraZeneca has hammered another stake in the ground with its newest asthma treatment, Airsupra.

    By Jan. 24, 2023
  • A prescription bottle with white pills and a wooden gavel sit atop a $100 bill showing Benjamin Franklin's face.
    Image attribution tooltip
    Bill Oxford via Getty Images

    Drug price negotiations: 5 key dates to watch

    As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.

    By Kelly Bilodeau • Jan. 23, 2023
  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas

    Already on a roll in oncology, Astellas hunts for big wins in other areas

    With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

    By Jan. 23, 2023
  • Bekki Brown UBC
    Image attribution tooltip
    Permission granted by Bekki Brown
    Q&A // First 90 Days

    UBC crowns Bekki Brown as its new CEO with a clear mandate to grow

    The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.

    By Jan. 20, 2023
  • The headquarters of the FDA, which has recently issued a recall for Teleflex air filters used in hospital respirators.
    Image attribution tooltip
    Sarah Silbiger/Getty Images via Getty Images

    FDA’s 2022 drug approvals fall short of recent norms

    The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.

    By Alexandra Pecci • Jan. 19, 2023
  • Novavax vaccine
    Image attribution tooltip
    Carsten Koall via Getty Images

    After ‘limping along,’ Novavax sees a path forward

    With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.

    By Jan. 18, 2023
  • Sean McCarthy, CEO and chairman, CytomX
    Image attribution tooltip
    Permission granted by CytomX

    A Moderna tie-up ushers in new era for CytomX

    The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

    By Jan. 18, 2023
  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    JuSun via Getty Images

    The M&A hunt is on — here are the prime targets

    Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.

    By Kelly Bilodeau • Jan. 17, 2023
  • Viewed from above, a rendering of the COVID-19 virus sits in the center of a clay, red basketball court.
    Image attribution tooltip
    Enes Evren via Getty Images

    Pro sports’ COVID protocols led to real-world data impacts for pharma

    After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

    By Jan. 16, 2023
  • financial storm
    Image attribution tooltip
    Stock via Getty Images

    How biotechs can weather the market storm

    Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

    By Jan. 13, 2023
  • International Space Station
    Image attribution tooltip
    iStock via Getty Images

    Space — the next frontier in drug development

    Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

    By Kelly Bilodeau • Jan. 12, 2023
  • M&A handshake
    Image attribution tooltip
    iStock via Getty Images

    Biopharma M&A may get the push it needs in 2023, but with a face lift

    A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

    By Jan. 12, 2023